Vivek Ramaswamy’s net worth stands at somewhere north of $1 billion, although there is no exact information about his personal wealth. Nonetheless, he is hailed as the youngest billionaire Republican Presidential candidate to date. Donald Trump had been the wealthiest Republican candidate so far. Ramaswamy also stood at the number one position in the 2016 “America’s Richest Entrepreneurs Under 40” list and was included in the “Richest 30 under 30” list.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Ramaswamy studied Bachelor of Science at Harvard and later earned a Doctor of Jurisprudence degree from Yale. Most of Ramaswamy’s wealth is tied to his biotechnology company Roivant Sciences (ROIV).
Ramaswamy’s Road to Success and Fame
Ramaswamy’s Roivant is a biotech holding company that acquires, develops, and commercializes often overlooked and ignored drugs. Roivant was founded in 2014 and went public in 2021 through a merger with a SPAC (Special Purpose Acquisition Company), which boosted the company’s valuation to $7.3 billion. Ramaswamy, who holds a 7% stake in Roivant, saw his fortune rise to $511 million at that time.
Aside from Roivant, Ramaswamy’s other notable biotech venture was Axovant. In 2015, Ramaswamy was involved in the largest IPO of any biotech company in the U.S. when he took Axovant public. The company raised $315 million and was valued at $3 billion. However, Axovant’s only Alzheimer’s drug failed in clinical trials.
Nevertheless, Ramaswamy then became instrumental in the filing of one of the largest IPOs of 2016, another biotech company in the U.S. called Myovant Sciences, which was spun off and listed on the Nasdaq, raising $218 million. Myovant was founded in April 2016, and by October 2016, the company made a notable deal with Takeda Pharmaceuticals (TAK) for a prostate cancer drug and a female infertility drug.
Come 2020, Ramaswamy’s net worth soared from the investment interest of Japanese company Sumitomo Dainippon. The company agreed to acquire a portfolio of five Roivant drugs and a 10% company stake for $3 billion. The sale added $176 million to Ramaswamy’s wealth that year. Following this event, Ramaswamy took Roivant public, as discussed above.
Ramaswamy Boasts Diversified Investments
Apart from Biotech, the young billionaire entrepreneur finds interest in other diversified investment fields. Some of his fortunes are tied across various assets such as stocks, bonds, Bitcoin (BTC-USD), Ethereum (ETH-USD), a stake in YouTube’s rival Rumble (RUM), and crypto payments platform MoonPay.
Interestingly, Ramaswamy ceded his CEO role in Roivant to join American politics. In 2021, he published his anti-woke book called “Woke,” which criticizes America’s growing focus on social issues. Ramaswamy argues that corporates must first focus on their customers and promote customer-excellence instead of driving attention to social and environmental issues.
He also founded an anti-woke investment company, Strive Asset Management, which boasts some notable investors, including Peter Thiel and Bill Ackman. The company is valued at roughly $300 million, with Ramaswamy holding $100 million.
Ramaswamy – The Politician
Then came the 2024 presidential campaign, which led to Trump’s notable win and the reason for Ramaswamy’s current political fame. Trump selected billionaire investor and Tesla (TSLA) CEO Elon Musk and Ramaswamy to co-head the Department of Government Efficiency (DOGE), which aims to curb excess spending and eliminate excessive regulation and federal charges.
Only 39, Ramaswamy is on a slow but steady path to becoming one of the biggest American billionaires. His business acumen and strong political stance have earned him a standing in the political realm and an influential role in the current Trump administration.
